Physician profile
Amy Lichtenfeld
NPI 1851356141
$17,111.84
in general payments reported to CMS, 2019-2025
43 companies · $3,154 in 2025
The $3,154 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,781 · 2020: $1,550 · 2021: $2,192 · 2022: $2,302 · 2023: $2,882 · 2024: $3,251 · 2025: $3,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,287.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,183.48 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,469.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $1,697.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,520.68 | 2020-2025 | Entyvio, Takhzyro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,361.62 | 2019-2024 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $1,211.50 | 2019-2025 | |
| Qol Medical, LLC | $802.52 | 2020-2025 | Sucraid, Sucraid |
| Kaleo, INC. | $733.37 | 2019-2024 | Auvi-Q |
| Greer Laboratories, INC. | $377.41 | 2019 | |
| Amgen INC. | $355.47 | 2019-2025 | Tezspire |
| Abbvie INC. | $341.78 | 2020-2025 | |
| Pfizer INC. | $326.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $280.37 | 2019-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $252.03 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $223.39 | 2020-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lichtenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.